Cargando…

Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS

PURPOSE: To assess clinical characteristics and device satisfaction of patients with chronic obstructive pulmonary disease (COPD) treated with glycopyrrolate/eFlow(®) Closed System (CS) nebulizer (further referred to as eFlow) under real-world conditions. PARTICIPANTS AND METHODS: Patients with COPD...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephenson, Judith J, Dembek, Carole, Caldwell-Tarr, Amanda, Conto, Rebecca M, Paullin, Mark, Kerwin, Edward M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369372/
https://www.ncbi.nlm.nih.gov/pubmed/32764916
http://dx.doi.org/10.2147/COPD.S248760
Descripción
Sumario:PURPOSE: To assess clinical characteristics and device satisfaction of patients with chronic obstructive pulmonary disease (COPD) treated with glycopyrrolate/eFlow(®) Closed System (CS) nebulizer (further referred to as eFlow) under real-world conditions. PARTICIPANTS AND METHODS: Patients with COPD currently using eFlow were identified by the study sponsor. Consenting patients who met study inclusion criteria completed a cross-sectional survey that included a device satisfaction questionnaire. Means, medians, and standard deviations were calculated. RESULTS: Sixty-six patients met inclusion criteria and completed the survey. Participants’ mean ± standard deviation age was 64.9 ± 11.9 years and the majority were white (86.4%) and female (59.1%). Almost two-thirds were former smokers. Thirty-nine (59.1%) reported their COPD to be severe/very severe and 38 (57.6%) reported a COPD exacerbation resulting in a hospitalization, ER visit, or medication modification over the past 12 months. Among 55 participants who had previously used another type of nebulizer, 44 (80%) were overall “much more”/“somewhat more” satisfied with the eFlow compared with their previous nebulizer(s). Regardless of prior nebulizer use, 60 (90.9%) participants were “satisfied”/“very satisfied” overall with the eFlow. Assembly and disassembly, operation, and cleaning were perceived as being “easy”/“very easy” by at least 65% of participants. Among all participants, 57 (86.4%) were “confident”/“very confident” of glycopyrrolate administration. On a Likert scale of 1 (“I don’t like it”) to 7 (“I like it a lot”), mean scores were at least 5.9 for portability, ease of cleaning, size, weight, short administration time, and relative silence of the device. Over 80% of participants said they “probably”/"definitely" would continue to use eFlow. CONCLUSION: Based on this real-world study, the majority of patients were highly satisfied with, and confident in, using eFlow.